DK1831369T3 - RNAI inhibering af serum af amyloid A til behandling af glaukom - Google Patents

RNAI inhibering af serum af amyloid A til behandling af glaukom

Info

Publication number
DK1831369T3
DK1831369T3 DK05855060.9T DK05855060T DK1831369T3 DK 1831369 T3 DK1831369 T3 DK 1831369T3 DK 05855060 T DK05855060 T DK 05855060T DK 1831369 T3 DK1831369 T3 DK 1831369T3
Authority
DK
Denmark
Prior art keywords
amyloid
glaucoma
serum
treatment
rnai inhibition
Prior art date
Application number
DK05855060.9T
Other languages
English (en)
Inventor
Abbot F Clark
Wan-Heng Wang
Loretta Mcnatt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1831369T3 publication Critical patent/DK1831369T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05855060.9T 2004-12-23 2005-12-19 RNAI inhibering af serum af amyloid A til behandling af glaukom DK1831369T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63870604P 2004-12-23 2004-12-23
PCT/US2005/046436 WO2006071691A2 (en) 2004-12-23 2005-12-19 Rnai inhibition of serum amyloid a for treatment of glaucoma

Publications (1)

Publication Number Publication Date
DK1831369T3 true DK1831369T3 (da) 2012-10-08

Family

ID=36440864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05855060.9T DK1831369T3 (da) 2004-12-23 2005-12-19 RNAI inhibering af serum af amyloid A til behandling af glaukom

Country Status (18)

Country Link
US (7) US20060172961A1 (da)
EP (1) EP1831369B1 (da)
JP (3) JP2008525469A (da)
KR (1) KR101311275B1 (da)
CN (2) CN101124322B (da)
AR (1) AR051848A1 (da)
AU (1) AU2005322228B2 (da)
BR (1) BRPI0516378A (da)
CA (1) CA2591403A1 (da)
DK (1) DK1831369T3 (da)
ES (1) ES2393325T3 (da)
MX (1) MX2007007388A (da)
PL (1) PL1831369T3 (da)
PT (1) PT1831369E (da)
SI (1) SI1831369T1 (da)
TW (1) TWI401316B (da)
WO (1) WO2006071691A2 (da)
ZA (1) ZA200704936B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947660B2 (en) 2005-03-11 2011-05-24 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
EP2192926A1 (en) * 2007-10-01 2010-06-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200930405A (en) 2007-11-15 2009-07-16 Alcon Res Ltd Low density lipoprotein receptor-mediated siRNA delivery
AR069704A1 (es) 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo
EP3584320A1 (en) 2008-09-25 2019-12-25 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CN101117644A (zh) * 2000-02-29 2008-02-06 阿尔康公司 青光眼的诊断和治疗药物
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
DK1309726T4 (da) * 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
US6455308B1 (en) * 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US20040072181A1 (en) * 2002-01-22 2004-04-15 Whitehead Alexander Steven Methods for determining drug responsiveness
CN1656222B (zh) * 2002-03-27 2011-11-30 艾格拉治疗公司 反义iap核碱基寡聚物及其应用
SI1504126T1 (sl) * 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US8729036B2 (en) * 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
US20040198967A1 (en) * 2002-09-04 2004-10-07 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Compositions and methods for tissue specific or inducible inhibition of gene expression
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉a基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20050137122A1 (en) * 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
US7718697B2 (en) * 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease

Also Published As

Publication number Publication date
WO2006071691A3 (en) 2006-11-16
US20100152279A1 (en) 2010-06-17
US20120122961A1 (en) 2012-05-17
CN101124322A (zh) 2008-02-13
ES2393325T3 (es) 2012-12-20
EP1831369A2 (en) 2007-09-12
JP2012193209A (ja) 2012-10-11
ZA200704936B (en) 2008-10-29
CN102172407A (zh) 2011-09-07
TW200634153A (en) 2006-10-01
KR101311275B1 (ko) 2013-09-27
BRPI0516378A (pt) 2008-09-02
CA2591403A1 (en) 2006-07-06
PT1831369E (pt) 2012-12-06
US20150225720A1 (en) 2015-08-13
AU2005322228B2 (en) 2011-08-11
AR051848A1 (es) 2007-02-14
US20110054008A1 (en) 2011-03-03
JP2008525469A (ja) 2008-07-17
MX2007007388A (es) 2007-08-23
JP2015044858A (ja) 2015-03-12
WO2006071691A2 (en) 2006-07-06
US20060172961A1 (en) 2006-08-03
US20140357692A1 (en) 2014-12-04
KR20070093118A (ko) 2007-09-17
PL1831369T3 (pl) 2013-07-31
AU2005322228A1 (en) 2006-07-06
SI1831369T1 (sl) 2013-01-31
EP1831369B1 (en) 2012-09-19
TWI401316B (zh) 2013-07-11
WO2006071691A8 (en) 2006-10-19
US20130123337A1 (en) 2013-05-16
CN101124322B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
DK1831369T3 (da) RNAI inhibering af serum af amyloid A til behandling af glaukom
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
CY2015030I2 (el) Ανταγωνιστικα αντισωματα il-17
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1730119T3 (da) Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
DK1802334T3 (da) Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DE602005023972D1 (de) Vereinfachte wafer-ausrichtung
NO20051873D0 (no) Antirotasjons-las
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK1630309T3 (da) Afløb
DE102006026707A8 (de) Duschwanne
DE502005005664D1 (de) Chronograph
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1784181T3 (da) VEGF-hæmning
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
DK1812002T3 (da) Behandling af mastitis
DK1756075T3 (da) Forbindelse til fremstilling af thiazol ved aminomethylering
DK1940447T3 (da) Behandling af neurodegenrative lidelser
AT500549B8 (de) Klärbecken
FI20041510A (fi) Menetelmä valettujen komponenttien valmistukseen